Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
← catalyst calendarSponsored by Corvus Pharmaceuticals, Inc. (industry) · CRVS — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
82actual
Sites
16
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-16 | actual | When the study began enrolling |
| Primary completion | 2026-01-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-24 | actual | The whole study's end, after follow-up |
| First posted | 2024-04-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Interventions
- Drug: Soquelitinib — also filed as CPI-818
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFIncidence of adverse events, changes in laboratory values, vital signs, and electrocardiograms
measured Up to 30 days after last intervention administration
Permalink · CRVS's whole pipeline · Catalyst calendar · Every registered study · What changed